linjc16/ctgov huggingface dataset:
Low Flow Anesthesia Without Initial High Flow Phase

Study Overview
=================
Brief Summary
-----------------
The aim of the study is to compare the effectiveness of conventional low flow anesthesia (LFA) with initial high fresh gas flow ( 4L/min) for 10 minutes and LFA with fixed fresh gas flow rate (1L/min).

Official Title
-----------------
Comparison of Low Flow Anesthesia With and Without Initial High Flow Phase

Conditions
-----------------
Low Flow Anesthesia, Volatile Anesthetic Consumption

Intervention / Treatment
-----------------
* Procedure: Conventional Low flow Anesthesia
* Procedure: Low Flow Anesthesia with fixed fresh gas flow rate


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ASA 1-3 scheduled for surgery under general anesthesia with endotracheal intubation Exclusion Criteria: hemodynamic instability emergency cases expected anesthesia duration < 60 min patient refusal

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Conventional group<br>After standart intravenous anesthesia induction end endotracheal intubation desflurane vaporizer will be set at 6% with fresh gas flow rate 4 L/min (50% O2, 50% air) until the EtAA concentration reaches 0.7 MAC (minimum alveolar concentration) Then, the desflurane vaporizer will be at a 1% higher value than the EtAA concentration required to achieve 0.7 MAC. And after 10 minutes fresh gas flow rate will be reduced to 1L/min. | Procedure: Conventional Low flow Anesthesia<br>* During the initial wash-in period 4 L/min Fresh gas flow will be used.<br>|
| Active Comparator: Fixed Fresh Gas Flow Rate group<br>After standart intravenous anesthesia induction end endotracheal intubation desflurane vaporizer will be set at 18% with fresh gas flow rate 1 L/min (50% O2, 50% air) until the EtAA concentration reaches 0.7 MAC (minimum alveolar concentration) Then, the desflurane vaporizer will be at a 2% higher value than the EtAA concentration required to achieve 0.7 MAC. | Procedure: Low Flow Anesthesia with fixed fresh gas flow rate<br>* Fresh gas flow rate will be 1 L/min throughout the procedure.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The time required to reach 0.7 MAC |  | perioperative | 
| number of adjustments made to the vaporizer settings | MAC will be held between 0.6-0.8 with adjustments at the vaporizer | perioperative | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| anesthetic agent consumption | desfluane consumption at the first hour and at the end of the surgery wil be recorded | perioperative |
A Study of Quantitative Assessments of Angle Width in Chinese Patients With Open-angle Glaucoma and/or Ocular Hypertension

Study Overview
=================
Brief Summary
-----------------
This study will assess angle width in Chinese patients with Open-angle Glaucoma and/or Ocular Hypertension.

Conditions
-----------------
Open-angle Glaucoma, Ocular Hypertension

Intervention / Treatment
-----------------
* Other: No Treatment


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Of Chinese descent Open-angle Glaucoma or Ocular Hypertension in each eye Exclusion Criteria: History of a narrow-angle or angle closure glaucoma Angle abnormalities in either eye

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| All Participants<br>Open-Angle Glaucoma (OAG) and/or Ocular Hypertension (OHT) patients. | Other: No Treatment<br>* No Treatment was given in this study.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Anterior Angle Width Using Anterior Segment Optical Coherence Tomography (AS OCT) | The angle width formed between the eye's cornea and iris in both eyes was measured in microns (µm) using AS OCT, a laser-based, noninvasive, diagnostic system providing high-resolution images of the eye. | Day 1 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of Study Eyes in Each Shaffer Grade Using Gonioscopic Lens | The angle width formed between the cornea and iris in both eyes was measured by gonioscopy using Shaffer grading where: grade 4=wide open, grade 3=moderately open, grade 2=moderately narrow, grade 1=very narrow or grade 0=closed. The number of eyes in each Shaffer Grade is reported. | Day 1 | 
| Number of Study Eyes in Each Step Grade Using Gonioscopic Lens | The angle width formed between the cornea and iris in both eyes was measured by gonioscopy using Large Step Grading ranging from 1.0 (smallest angle width) to 7.5 (largest angle width) with 0.5 unit intervals where each Large Step unit represented a fixed length of approximately 200 µm. The number of eyes in each Large Step Grade is reported. | Day 1 |
Compliance With Once Daily Glaucoma Medication

Study Overview
=================
Brief Summary
-----------------
A study to examine patient compliance with once daily glaucoma medication

Official Title
-----------------
Compliance With Once Daily Glaucoma Medication

Conditions
-----------------
Compliance

Intervention / Treatment
-----------------
* Behavioral: Intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Primary open angle glaucoma or ocular hypertension patients Exclusion Criteria: None
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Intervention group<br>The intervention group watched an educational video, reviewed current barriers to drop-taking and possible solutions with a study coordinator, received regular phone call reminders, and had audible and visible reminders activated on their DA devices. | Behavioral: Intervention<br>* The intervention group watched an educational video, reviewed current barriers to drop-taking and possible solutions with a study coordinator, received regular phone call reminders, and had audible and visible reminders activated on their DA devices.<br>|
| Non-Intervention Group<br>The control group was told to take drops as prescribed and received no additional intervention. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Physical Training and Blood Pressure in High Risk Youths

Study Overview
=================
Brief Summary
-----------------
To determine the effects of physical activity on blood pressure and body fat in children varying in ethnicity, gender, and health status.

Detailed Description
-----------------
DESIGN NARRATIVE: There were two specific aims. The first was to test the hypothesis that controlled physical training (PT) reduced blood pressure, at rest and in reaction to forehead cold and exercise stressors, in 8-9 year olds who were high in both blood pressure and body fatness. Subjects were divided equally on gender and blood pressure and body fatness. Subjects were divided equally on gender and ethnicity (black/white). Both resting and reactive blood pressure were correlated with left ventricular mass and were predictive of future essential hypertension. The underlying hemodynamic regulators of blood pressure, cardiac output and the total peripheral resistance, were measured with impedance cardiography to explore hemodynamic mechanisms through which training had a favorable influence on blood pressure and left ventricular mass. The second aim tested the hypothesis that physical training reduced percent body fat, as measured with dual energy x-ray absorptiometry (DEXA). Children above the 70th percentile in both blood pressure and fatness were randomly assigned, within ethnicity and gender, to a physical training or waiting list control group. After the physical training group underwent four months of training, all subjects were retested and these data were used to test the primary hypotheses. The initial control subjects then performed four months of physical training, after which they were retested. The data from this second phase were added to the data of the initial physical training group to explore interactions of training with gender and ethnicity. The initial physical training group was brought back four months after cessation of training to see if the changes elicited by the training were reversible. To document the stimulation provided by the training, heart rate was monitored during training sessions. To observe the time course of changes between the full lab testing sessions, skinfolds and resting blood pressure were measured monthly. Diet and free living physical activity were assessed to help explain changes in body composition. Aerobic fitness was measured with treadmill tests of maximal oxygen consumption.

Conditions
-----------------
Cardiovascular Diseases, Heart Diseases, Hypertension, Obesity

Participation Criteria
=================
Eligibility Criteria
-----------------
No eligibility criteria

Ages Eligible for Study
-----------------
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Electrical Stimulation to Strengthen Muscles in the Lower Legs in Patients Requiring Prolonged Mechanical Ventilation

Study Overview
=================
Brief Summary
-----------------
The primary aim of this proposal is to test the effectiveness of NMES in improving functional status and muscle function in patients requirng prolonged mechanical ventilation

Official Title
-----------------
Electrical Stimulation to Strengthen the Quadriceps Muscles in Patients Requiring Prolonged Mechanical Ventilation

Conditions
-----------------
Muscle Weakness

Intervention / Treatment
-----------------
* Device: Neuromuscular electrical stimulation
* Device: sham stimulation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: duration of mechanical ventilation for 14 days or more sufficiently awake able to speak and comprehend English Exclusion Criteria: known primary neuromuscular disease lower extremities paresis or amputee patients with left-ventricular assist device (LVAD) cardiopulmonary instability

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Neuromuscular electrical stimulation<br>Neuromuscular electrical stimulation (NMES) will be applied to the quadriceps muscles for 30 minutes | Device: Neuromuscular electrical stimulation<br> <br> * Other names: 300PV™ neuromuscular stimulation (NMES)device;|
| Sham Comparator: Sham stimulation<br>Sham stimulation will be applied to the quadriceps for 30 minutes | Device: sham stimulation<br>* sham stimulation will be applied to the quadriceps<br>* Other names: 300PV™ Neuromuscular Stimulation (NMES) device;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| modified Functional Independence Measurement (FIM) score | Functional status as measured by modified Functional Independence Measurement (FIM) score | Hospital discharge, an expected average stay of 5 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
muscle strength, muscle function, functional status
Acute Kidney Injury and Acute Kidney Disease in COVID-19

Study Overview
=================
Brief Summary
-----------------
Acute kidney injury (AKI) has been identified as an independent risk factor for in-hospital mortality. The present study aims to investigate the incidence of AKI and renal recovery of inpatients diagnosed with COVID-19.

Detailed Description
-----------------
Beginning in December 2019, a novel coronavirus, designated as severe acute respiratory distress coronavirus 2 (SARS-CoV-2), has caused an international outbreak of respiratory illness termed coronavirus disease 2019 (COVID-19). Although the clinical manifestations of COVID-19 are dominated by respiratory symptoms, some patients show severe kidney abnormalities. Acute kidney injury (AKI) has been identified as an independent risk factor for in-hospital mortality. The present study aims to investigate the incidence of AKI and renal recovery of inpatients diagnosed with COVID-19.

Official Title
-----------------
Acute Kidney Injury (AKI) and Acute Kidney Disease (AKD) in Patients With Coronavirus Disease 2019 (COVID-19)

Conditions
-----------------
Acute Kidney Injury, Corona Virus Infection

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 1) Patients with COVID-19 diagnosed by World Health Organisation (WHO) criteria Exclusion Criteria: Patients aged less than 18 years Patients with stage 4 chronic kidney disease (baseline estimated glomerular filtration rate <30 ml/min/1.73 m2) Patients receiving maintenance dialysis Recipients of solid-organ transplantation

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| ICU patients<br>Inpatients with COVID-19 requiring ICU care | |
| Non-ICU patients<br>Inpatients with COVID-19 not requiring ICU care | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of AKI | Serial assessment of serum creatinine and urine output | 30 days post-hospital admission | 
| Cystatin C as indicator of mortality | All-cause mortality | 30 days post-hospital admission | 
| Cystatin C as indicator of renal disease | AKI and acute kidney disease (AKD) | 30 days post-hospital admission | 
| Cystatin C as indicator of respiratory illness | Ventilator-free days | 30 days post-hospital admission | 
| Cystatin C as indicator of disease severity | Rate of intensive care unit admission | 30 days post-hospital admission |
A Drug-Drug Interaction Study of Warfarin and PA21

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine if Warfarin is affected by PA21.

Official Title
-----------------
A Single-centre, Open-label, Three-period Study of the Pharmacokinetic Effect of PA21 on Warfarin in Healthy Male and Female Adults

Conditions
-----------------
Drug Interaction Potentiation

Intervention / Treatment
-----------------
* Drug: PA21
* Drug: Warfarin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy volunteers Written informed consent Exclusion Criteria: No significant medical conditions Pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: PA21 and Warfarin with food<br>The maximum dose of PA21 will be 15.0 g/day. The maximum dose of Warfarin will be 10 mg/day | Drug: PA21<br>* The maximum dose of PA21 will be 15.0 g/day.<br>Drug: Warfarin<br>* The maximum dosage of Warfarin will be 10 mg/day<br>|
| Experimental: No PA21; Warfarin with food<br>The maximum dosage of Warfarin will be 10 mg/day | Drug: Warfarin<br>* The maximum dosage of Warfarin will be 10 mg/day<br>|
| Experimental: PA21 with food and Warfarin 2hrs later<br>The maximum dose of PA21 will be 15 g/day. The maximum dose of Warfarin will be 10 mg/day | Drug: PA21<br>* The maximum dose of PA21 will be 15.0 g/day.<br>Drug: Warfarin<br>* The maximum dosage of Warfarin will be 10 mg/day<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Area Under the Curve from time zero to 24 hours (AUC0-24) | Area under the plasma concentration versus time curve from time zero (pre-dose) to 24 hours | pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 120, 144 and 168 hours post Warfarin dose on Days 0, 11, 22 | 
| Area Under the Curve from time zero to infinite (AUC0-infinity) | Area under the plasma concentration versus time curve from time zero (pre-dose) to extrapolated infinite time | pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 120, 144 and 168 hours post Warfarin dose on Days 0, 11, 22 | 
| Maximum observed plasma concentration (Cmax) |  | pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 120 and 168 hours post Warfarin dose on days 0, 11, 22 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Drug-drug interaction, Pharmacokinetics, PA21
Propofol Versus Midazolam With Fentanyl for EGD Endomicroscopy

Study Overview
=================
Brief Summary
-----------------
This trial aims to compare the endomicroscopic image quality and sedation efficacy of propofol or midazolam with fentanyl.

Conditions
-----------------
Gastritis, Functional Dyspepsia

Intervention / Treatment
-----------------
* Drug: propofol
* Drug: midazolam with fentanyl


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: outpatients attending endomicroscopy able to give written informed consent Exclusion Criteria: GI tract malignancy coagulopathy acute upper digestive tract bleeding pregnancy or breast feeding allergy to fluorescein sodium impaired renal function

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br>sedation using propofol | Drug: propofol<br>* conscious sedation using propofol<br>|
| Experimental: 2<br>sedation using midazolam with fentanyl | Drug: midazolam with fentanyl<br>* conscious sedation using midazolam with fentanyl<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| endomicroscopic image quality |  | 3 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| sedation efficacy outcomes,patient assessment,physician assessment |  | 3 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
normal
Developmental Effects of Infant Formula Supplemented With LCPUFA

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to compare the effects on visual development, growth, cognitive development, tolerance, and blood chemistry parameters in term infants fed one of four study formulas containing various levels of DHA and ARA.

Conditions
-----------------
Cognitive Development, Growth

Intervention / Treatment
-----------------
* Other: DHA and ARA
* Other: Control


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: healthy, term, formula fed infants from 1-5 days of age Exclusion Criteria: history of disease that effects normal growth and development breast fed, or formula intolerance

Ages Eligible for Study
-----------------
Minimum Age: 1 Day
Maximum Age: 5 Days

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br> | Other: DHA and ARA<br>* various levels of DHA and ARA<br>|
| Experimental: 2<br> | Other: DHA and ARA<br>* various levels of DHA and ARA<br>|
| Experimental: 3<br> | Other: DHA and ARA<br>* various levels of DHA and ARA<br>|
| Other: 4<br>Control | Other: Control<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| visual development |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cognitive development |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
infant formula, visual development